Form 8-K - Current report:
SEC Accession No. 0001193125-25-157867
Filing Date
2025-07-11
Accepted
2025-07-11 08:34:05
Documents
14
Period of Report
2025-07-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d826245d8k.htm   iXBRL 8-K 39407
2 EX-99.1 d826245dex991.htm EX-99.1 18119
6 GRAPHIC g826245g0711081736920.jpg GRAPHIC 1643
  Complete submission text file 0001193125-25-157867.txt   193775

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikna-20250711.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikna-20250711_lab.xml EX-101.LAB 19500
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikna-20250711_pre.xml EX-101.PRE 12168
16 EXTRACTED XBRL INSTANCE DOCUMENT d826245d8k_htm.xml XML 3908
Mailing Address 50 NORTHERN AVE. BOSTON MA 02210
Business Address 50 NORTHERN AVE. BOSTON MA 02210 857-343-8292
Ikena Oncology, Inc. (Filer) CIK: 0001835579 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40287 | Film No.: 251117583
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)